Reply
暂无分享,去创建一个
We appreciate Drs. Bubb and Johnson's potential biological inferences to explain the increased mortality shortly after discontinuation of febuxostat or allopurinol in the CARES trial. We also note that the findings could be methodologically explained by "sick-stopper" and "healthy-adherer" effects. Gravely ill or fatally sick individuals are more likely to discontinue preventive treatments (such as urate-lowering therapy) for largely asymptomatic non-fatal conditions. This article is protected by copyright. All rights reserved.
[1] H. Jinnah,et al. Shortage of Cellular ATP as a Cause of Diseases and Strategies to Enhance ATP , 2019, Front. Pharmacol..
[2] Deepak L. Bhatt,et al. Non-adherence to cardiovascular medications. , 2014, European heart journal.
[3] Anna C. Balazs,et al. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. , 1980, The New England journal of medicine.